Skip to Main Content

Paper Details

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clin Pharmacol Ther
25
2021
CYP2C19, CYP2C19 *1/*17, CYP2C19*17 Allele, CYP2C19*17 allele, Clopidogrel, Patients, atherothrombotic, atherothrombotic events, clopidogrel, cytochrome P450 2C19 isozyme, normal metabolizers, patient, patients, prasugrel, ticagrelor
Author NameAffiliation
Amber L BeitelsheesUniversity of Maryland School of Medicine
Sony TutejaUniversity of Pennsylvania Perelman School of Medicine
Nita A LimdiUniversity of Alabama at Birmingham
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida
Karen E WeckDivision of Cardiology and McAllister Heart Institute, UNC School of Medicine, University of North Carolina at Chapel Hill
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida
Larisa H CavallariDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida
  • 1 - 8

Datasets

Release 1.2